Angiodynamics Inc: Form 10-K for the period ended May 31, 2023
Filed with the SEC on Aug 3, 2023 and accepted by EDGAR at Aug 3, 2023, 17:16 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-05-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2022-06-01 to 2023-05-31 | $338.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months2022-06-01 to 2023-05-31 | $164.5m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 12 months2022-06-01 to 2023-05-31 | $174.2m | us-gaap:GrossProfit |
| Research and development | 12 months2022-06-01 to 2023-05-31 | $29.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2022-06-01 to 2023-05-31 | −$51.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2022-06-01 to 2023-05-31 | $2.7m | us-gaap:InterestExpense |
| Income tax | 12 months2022-06-01 to 2023-05-31 | −$2.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2022-06-01 to 2023-05-31 | −$52.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2022-06-01 to 2023-05-31 | −$1.33 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2022-06-01 to 2023-05-31 | −$1.33 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2022-06-01 to 2023-05-31 | 39,480,367 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2022-06-01 to 2023-05-31 | $78.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2022-06-01 to 2023-05-31 | $3.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-05-31 | $44.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-05-31 | $163.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-05-31 | $532.6m | us-gaap:Assets |
| Current liabilities | At period end2023-05-31 | $83.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-05-31 | $154.3m | us-gaap:Liabilities |
| Long-term debt | At period end2023-05-31 | $49.8m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2023-05-31 | $378.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-23-027335. Last ingested by Listed: Oct 30, 2026, 16:23 ET. Listed shows no prices and gives no investment advice.